Identity
- Security key
- 11751
- Ticker
- ANVS
- Type
- CS — Common Stock
- Exchange
- New York Stock Exchange(XNYS)
- Venue group
- NYSE
- Operating MIC
- XNYS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2020-01-29
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- ANVS
Detail
Enriched 2026-08-14 20:47
- Market cap
- $76,575,362.4
- Shares outstanding (class)
- 34,646,868
- Shares outstanding (weighted)
- 42,541,868
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 7
- Location
- MALVERN, PA
- Homepage
- https://www.annovisbio.com
- Description
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.